OP Asset Management’s Pacira BioSciences PCRX Stock Holding History

OP Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-22,827	Closed	-$591K	–	865
2025 Q4	$591K	Buy	22,827 +13,639	+148%	+$324K	0.01%	638
2025 Q3	$237K	Buy	+9,188	New	+$226K	﹤0.01%	721

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OP Asset Management's PCRX Position: Q1 2026 in Review

OP Asset Management sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 22,827 shares — an estimated $591K sold.

OP Asset Management first reported a position in PCRX in Q3 2025 and held it in 2 quarters. The position peaked at $591K in Q4 2025. 242 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

OP Asset Management reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
OP Asset Management sold 22,827 Pacira BioSciences shares in Q1 2026, an estimated $591K.
OP Asset Management first reported a position in Pacira BioSciences in Q3 2025 and held it in 2 quarters.
OP Asset Management's Pacira BioSciences position peaked at $591K in Q4 2025.
242 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on OP Asset Management's 13F filing for Q1 2026, filed 9 Apr 2026.